Article summary
The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a public consultation on the International Council for Harmonisation (ICH) M15 guideline for Model Informed Drug Development (MIDD). The guideline, which has reached Step 2b in the ICH process, aims to establish a harmonised assessment framework for MIDD evidence, including recommendations for planning, model evaluation, and documentation. The MHRA participated in the drafting process and is now seeking input from stakeholders until 31 March 2025.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial